tirzepatide court case update Lilly, Novo Fight Weight Loss Drug Compounders Over Shortage FDA Allows Compounded Tirzepatide During

A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome

Lilly removed this from the slide deck, but I managed to snag a picture at the presentation We can see the women in the trial were already at 30.8% weight loss at 80 weeks on the max dose with the 9mg dose only 2% behind and both still losing weight

Declining energy over weeks may indicate insufficient caloric or protein intake

Simultaneously, its GLP-1 receptor agonist activity stimulates glucose-dependent insulin release, suppresses glucose-dependent glucagon secretion, slows gastric emptying, and promotes satiety through central appetite regulation

D.JacquotJ